In patients with NSCLC CNS disease, mutations in EGFR (36% vs 17%, P < .001) and KRAS (18% vs 14%, P = .19) were more frequent than in the non-CNS cohort (Figure 3B). This evidence concerns the gene EGFR and non-small cell lung carcinoma.